Inflammatory Bowel Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?
The 7 major inflammatory bowel disease markets are expected to exhibit a CAGR of 2.76% during 2024-2034.
The inflammatory bowel disease market has been comprehensively analyzed in IMARC’s new report titled “Inflammatory Bowel Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Inflammatory bowel disease (IBD) is a term mainly used to describe two disorders, Crohn’s disease and ulcerative colitis, that are characterized by the chronic inflammation of the gastrointestinal tract. It tends to occur in the case of genetically susceptible individuals after an exaggerated immune response to a normal stimulus comprising food and intestinal flora. Inflammatory bowel disease symptoms tend to vary, depending on the severity of inflammation and the region where it occurs. The signs and symptoms that are observed in Crohn’s disease and ulcerative colitis comprise diarrhea, fatigue, abdominal pain and cramping, blood in the stool, reduced appetite and unintended weight loss, mouth sores, pain or drainage near and around the anus owing to infection from a tunnel into the skin (fistula), etc. The diagnosis of IBD requires a combination of clinical and imaging findings, inflammatory laboratory markers, and endoscopic biopsies. The hematological findings will include microcytic anemia, leukocytosis, and thrombocytosis. In the case of a positive result, inflammatory markers such as erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP) are elevated.
The increasing prevalence of inflammatory gastrointestinal disorders owing to several associated factors, such as genetic predisposition, environmental triggers, immune system disturbances, etc., is primarily driving the inflammatory bowel disease market. In addition to this, the widespread adoption of various diagnostic procedures, including comprehensive metabolic panels, serologic markers, inflammation markers, etc., for early diagnosis of the disease is further propelling the market growth. Moreover, the escalating utilization of corticosteroids as the first line of treatment and their easy availability at retail pharmacy stores are also acting as significant growth-inducing factors. Apart from this, the emerging popularity of biologic and biosimilar drugs over traditional treatment options owing to their enhanced efficacy is further bolstering the global market. Additionally, the growing usage of pre-biotic and pro-biotic food products to improve gut health is also creating a positive outlook for the market. Besides this, the ongoing development of novel therapies with a better clinical profile and a patient-friendly RoA (route of administration) is further augmenting the global market. Numerous other factors, including the escalating utilization of single-cell RNA analysis to understand the molecular basis of the disease and the rising penetration of targeted and advanced therapies, are expected to drive the inflammatory bowel disease market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the inflammatory bowel disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for inflammatory bowel disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the inflammatory bowel disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the inflammatory bowel disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the inflammatory bowel disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current inflammatory bowel disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the inflammatory bowel disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the inflammatory bowel disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the inflammatory bowel disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the inflammatory bowel disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of inflammatory bowel disease?
What will be the growth rate of patients across the seven major markets?
Inflammatory Bowel Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for inflammatory bowel disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the inflammatory bowel disease market?
The inflammatory bowel disease market has been comprehensively analyzed in IMARC’s new report titled “Inflammatory Bowel Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Inflammatory bowel disease (IBD) is a term mainly used to describe two disorders, Crohn’s disease and ulcerative colitis, that are characterized by the chronic inflammation of the gastrointestinal tract. It tends to occur in the case of genetically susceptible individuals after an exaggerated immune response to a normal stimulus comprising food and intestinal flora. Inflammatory bowel disease symptoms tend to vary, depending on the severity of inflammation and the region where it occurs. The signs and symptoms that are observed in Crohn’s disease and ulcerative colitis comprise diarrhea, fatigue, abdominal pain and cramping, blood in the stool, reduced appetite and unintended weight loss, mouth sores, pain or drainage near and around the anus owing to infection from a tunnel into the skin (fistula), etc. The diagnosis of IBD requires a combination of clinical and imaging findings, inflammatory laboratory markers, and endoscopic biopsies. The hematological findings will include microcytic anemia, leukocytosis, and thrombocytosis. In the case of a positive result, inflammatory markers such as erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP) are elevated.
The increasing prevalence of inflammatory gastrointestinal disorders owing to several associated factors, such as genetic predisposition, environmental triggers, immune system disturbances, etc., is primarily driving the inflammatory bowel disease market. In addition to this, the widespread adoption of various diagnostic procedures, including comprehensive metabolic panels, serologic markers, inflammation markers, etc., for early diagnosis of the disease is further propelling the market growth. Moreover, the escalating utilization of corticosteroids as the first line of treatment and their easy availability at retail pharmacy stores are also acting as significant growth-inducing factors. Apart from this, the emerging popularity of biologic and biosimilar drugs over traditional treatment options owing to their enhanced efficacy is further bolstering the global market. Additionally, the growing usage of pre-biotic and pro-biotic food products to improve gut health is also creating a positive outlook for the market. Besides this, the ongoing development of novel therapies with a better clinical profile and a patient-friendly RoA (route of administration) is further augmenting the global market. Numerous other factors, including the escalating utilization of single-cell RNA analysis to understand the molecular basis of the disease and the rising penetration of targeted and advanced therapies, are expected to drive the inflammatory bowel disease market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the inflammatory bowel disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for inflammatory bowel disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the inflammatory bowel disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the inflammatory bowel disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the inflammatory bowel disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current inflammatory bowel disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the inflammatory bowel disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the inflammatory bowel disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the inflammatory bowel disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the inflammatory bowel disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of inflammatory bowel disease?
What will be the growth rate of patients across the seven major markets?
Inflammatory Bowel Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for inflammatory bowel disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the inflammatory bowel disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INFLAMMATORY BOWEL DISEASE - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 INFLAMMATORY BOWEL DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INFLAMMATORY BOWEL DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 INFLAMMATORY BOWEL DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INFLAMMATORY BOWEL DISEASE - UNMET NEEDS
10 INFLAMMATORY BOWEL DISEASE - KEY ENDPOINTS OF TREATMENT
11 INFLAMMATORY BOWEL DISEASE - MARKETED PRODUCTS
11.1 List of Inflammatory Bowel Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Tofacitinib - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Adalimumab
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ustekinumab - Janssen Biotech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Mesalazine - Tillotts Pharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Balsalazide - Salix Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 INFLAMMATORY BOWEL DISEASE - PIPELINE DRUGS
12.1 List of Inflammatory Bowel Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 VC 005 - Jiangsu Vcare Pharmatech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PF 6480605 - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Izencitinib - Theravance Biopharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 QBECO - Qu Biologics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MORF 057 - Morphic Therapeutic
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. INFLAMMATORY BOWEL DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 INFLAMMATORY BOWEL DISEASE - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Inflammatory Bowel Disease - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Inflammatory Bowel Disease - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Inflammatory Bowel Disease - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Inflammatory Bowel Disease - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Inflammatory Bowel Disease - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Inflammatory Bowel Disease - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Inflammatory Bowel Disease - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Inflammatory Bowel Disease - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Inflammatory Bowel Disease - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Inflammatory Bowel Disease - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Inflammatory Bowel Disease - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Inflammatory Bowel Disease - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Inflammatory Bowel Disease - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Inflammatory Bowel Disease - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Inflammatory Bowel Disease - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Inflammatory Bowel Disease - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
15 INFLAMMATORY BOWEL DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 INFLAMMATORY BOWEL DISEASE MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INFLAMMATORY BOWEL DISEASE - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (?2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 INFLAMMATORY BOWEL DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 INFLAMMATORY BOWEL DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 INFLAMMATORY BOWEL DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 INFLAMMATORY BOWEL DISEASE - UNMET NEEDS
10 INFLAMMATORY BOWEL DISEASE - KEY ENDPOINTS OF TREATMENT
11 INFLAMMATORY BOWEL DISEASE - MARKETED PRODUCTS
11.1 List of Inflammatory Bowel Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Tofacitinib - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Adalimumab
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ustekinumab - Janssen Biotech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Mesalazine - Tillotts Pharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Balsalazide - Salix Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 INFLAMMATORY BOWEL DISEASE - PIPELINE DRUGS
12.1 List of Inflammatory Bowel Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 VC 005 - Jiangsu Vcare Pharmatech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PF 6480605 - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Izencitinib - Theravance Biopharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 QBECO - Qu Biologics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MORF 057 - Morphic Therapeutic
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. INFLAMMATORY BOWEL DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 INFLAMMATORY BOWEL DISEASE - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Inflammatory Bowel Disease - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Inflammatory Bowel Disease - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Inflammatory Bowel Disease - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Inflammatory Bowel Disease - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Inflammatory Bowel Disease - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Inflammatory Bowel Disease - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Inflammatory Bowel Disease - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Inflammatory Bowel Disease - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Inflammatory Bowel Disease - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Inflammatory Bowel Disease - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Inflammatory Bowel Disease - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Inflammatory Bowel Disease - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Inflammatory Bowel Disease - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Inflammatory Bowel Disease - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Inflammatory Bowel Disease - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Inflammatory Bowel Disease - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Inflammatory Bowel Disease - Access and Reimbursement Overview
15 INFLAMMATORY BOWEL DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 INFLAMMATORY BOWEL DISEASE MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
